TOP2A and prostate cancer: Aberrant expression of TOP2A has been identified in many tumors, including lung adenocarcinoma, hepatocellular carcinoma, adrenocortical carcinoma, neuroblastic tumors, prostate cancer, and breast cancer (de Resende et al., 2013; Jain et al., 2013; Moretti et al., 2013; Chen et al., 2016; Du et al., 2020; Zeng et al., 2020).